Last reviewed · How we verify
Atenativ
At a glance
| Generic name | Atenativ |
|---|---|
| Also known as | antithrombin concentrate |
| Sponsor | Octapharma |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B (PHASE3)
- Study of Hemostasis in Patients With Congenital Disorder of Glycosylation
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (PHASE3)
- Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass (PHASE3)
- Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia
- Prediction of Mortality and Morbidity After Hip Fracture Using Monocyte Distribution Width (MDW)
- Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
- Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atenativ CI brief — competitive landscape report
- Atenativ updates RSS · CI watch RSS
- Octapharma portfolio CI